Heart failure market to grow at 9.6 per cent CAGR in 7MM during 2022-32
GlobalData’s report reveals that the US will contribute the most to the growth of the HF market due to the higher prevalence of HF…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
KERENDIA
FINEARTS-HF trial results in clinically meaningful reduction in the composite endpoint of CV death
The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which…
Bayer introduces medication for Chronic Kidney Disease
The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease…
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes
It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…